Table 2

Baseline KRAS mutations and clinicopathological findings

Baseline KRAS mutationTotal
AbsentPresent
Age groups
 <60110 (86.6%)17 (13.4%)127
 >6026 (81.3%)6 (18.8%)32
 Total136 (85.5%)23 (14.5%)159
Sex
 Male66 (88.0%)9 (12.0%)75
 Female71 (83.5%)14 (16.5%)85
 Total137 (85.6%)23 (14.4%)160
Metaplasia at baseline
 Absent25 (80.6%)6 (19.4%)31
 Present112 (86.8%)17 (13.2%)129
 Total137 (85.6%)23 (14.4%)160
Lymphocytes in stroma
 Mild + moderate118 (86.7%)18 (13.3%)136
 Severe19 (79.2%)5 (20.8%)24
 Total137 (85.6%)23 (14.4%)160